Menu   WellSpan Health
Banner _Screen

Oncology Services

Oncology Services

Treatment Studies

The York Cancer Center strives to bring the most current cancer therapies available to our community, with respect to treatment, symptom management, and prevention. We continue to collaborate in a large number of National Cancer Institute and industry-sanctioned cooperative group trials. These collaborations have allowed us the opportunity to help bring some cancer treatments to our community that would normally be available only at larger centers or universities.

Our research team continually works to provide the community with a variety of treatment trials. The research team is a dedicated group of professionals who work in conjunction with physicians, nurses and patients to facilitate enrollment in clinical trials, provide protocol therapy and detail collection of research data, which is then submitted to the statistical centers.

Below is a list of the cancer treatment clinical trials that are currently available to our patients in the community. To learn more about these studies, talk to your physician or the York Cancer Center.

NRG-BN001 - Open ACC and YCC


Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma

Record Created: 2014-10-16 10:21:02

Are Memory Changes Precipitated by Endocrine Therapy Treatment in Breast Cancer Patients Previously Treated with Chemotherapy


Are Memory Changes Precipitated by Endocrine Therapy Treatment in Breast Cancer Patients Previously Treated with Chemotherapy

Record Created: 2011-07-11 11:39:08



Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)

Record Created: 2015-06-18 13:52:59



A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Muti-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Record Created: 2015-04-15 13:09:55



A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Record Created: 2015-08-11 14:30:30

NSABP B-50-I - Screening Closed


NSABP B-50-I: A Randomized, Multicenter, Open Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy

Record Created: 2013-04-01 15:19:52



A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Record Created: 2013-04-17 12:58:05

PBI 3.0 - Open @ York Only


Multi-Institutional Randomized Trial of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with ER Negative Early Stage Breast Cancer (PBI 3.0)

Record Created: 2014-02-12 15:11:23

SWOG S1207


Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of EVEROLIMUS in Patients with High-Risk Hormone Receptor-Positive AND HER2/neu Negative Breast Cancer. “e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.”

Record Created: 2013-10-08 10:03:41

York Cancer Center Patient Registry


York Cancer Center Patient Registry: A Study to Compile Information on the Efficacy of High Dose Rate (HDR) Brachytherapy in Providing Radiation Therapy to Breast Cancer Patients

Record Created: 2006-04-03 17:04:28

GOG 0238


A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus

Record Created: 2015-03-11 16:19:48



Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Peritoneal Cancer Progression-Free Survival?

Record Created: 2014-08-13 13:37:50



A Phase III Randomized Trial of Gemcitabine (NSC#613327) Plus Docetaxel (NSC#628503) Followed by Doxorubicin (NSC#123127) Versus Observation for Uterus-Limited, High Grade Uterine Leiomyosarcoma

Record Created: 2014-11-10 10:24:18

NRG-GY002 - temporary suspension


A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer

Record Created: 2015-06-18 14:01:19

RTOG 0920

Head & Neck

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally Advanced Resected Head ad Neck Cancer

Record Created: 2010-02-02 14:58:20

Alliance A041202


A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Record Created: 2013-12-24 08:07:04

ECOG E2906 - Suspended to Enrollment


Phase III Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years)

Record Created: 2011-01-31 15:30:48

CALGB C30610/RTOG 0538


Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

Record Created: 2008-04-23 14:13:40

SWOG S1400


S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Record Created: 2014-07-29 13:04:26

SWOG S1403


"A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)"

Record Created: 2015-05-07 09:41:41

ECOG E1412


Randomized Phase II open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma

Record Created: 2013-08-19 12:33:19

ECOG E1A11 - suspended to enrollment

Multiple Myeloma

Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MantenANCE in Patients with Newly DIagnosed Sympotmatic Multiple Myeloma (ENDURANCE)

Record Created: 2013-11-26 08:53:17


Polycythemia Vera

Prospective, Non-interventional Study of Disease Progression and Treatment of Patients With Polycythemia Vera in United States Academic or Community Clinical Practices

Record Created: 2015-03-26 16:17:23



Phase III Trial of Enzalutamide (NSC #766085) versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

Record Created: 2014-01-23 09:08:17

RTOG 0815


A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer

Record Created: 2009-10-09 11:57:57

RTOG 0924 - QOL closed to accrual


Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Record Created: 2011-08-04 15:26:29

ECOG- ACRIN EAY131 Sub-Study B

Solid Tumor/Lymphoma

Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations

Record Created: 2015-08-18 15:06:28

ECOG- ACRIN EAY131 Sub-Study E

Solid Tumor/Lymphoma

Testing AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR

Record Created: 2015-08-18 15:07:56

ECOG- ACRIN EAY131 Sub-Study F

Solid Tumor/Lymphoma

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations

Record Created: 2015-06-18 13:56:23

ECOG- ACRIN EAY131 Sub-Study G

Solid Tumor/Lymphoma

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)

Record Created: 2015-06-18 13:58:18

ECOG- ACRIN EAY131 Sub-Study H

Solid Tumor/Lymphoma

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)

Record Created: 2015-06-18 13:59:27

ECOG- ACRIN EAY131 Sub-Study Q

Solid Tumor/Lymphoma

Ado-trastuzumab Emtansine in Patients with Tumors with HER2 Amplification (Except Breast and Gastric/Gastro-Esophageal Junction (GEJ) Adenocarcinomas)

Record Created: 2015-08-18 15:13:45

ECOG- ACRIN EAY131 Sub-Study R

Solid Tumor/Lymphoma

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol R: Phase II Study of Trametinib in patients with BRAF fusions, or with non-V600E, nonV600K BRAF mutations

Record Created: 2015-06-18 14:00:15

ECOG- ACRIN EAY131 Sub-Study U

Solid Tumor/Lymphoma

VS-6063 (defactinib) in Patients with Tumors with NF2 Loss

Record Created: 2015-08-18 15:14:49

ECOG- ACRIN EAY131 Sub-Study V

Solid Tumor/Lymphoma

Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)

Record Created: 2015-08-18 15:16:11

ECOG-ACRIN EAY131 Screening

Solid Tumor/Lymphoma

Molecular Analysis for Therapy Choice (MATCH)

Record Created: 2015-06-18 13:54:38


Solid Tumor/Lymphoma

Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment

Record Created: 2015-08-18 15:04:32

Are you sure you would like to cancel?

All information will be lost.

Yes No ×

About the provider search

This search will provide you with WellSpan Medical Group and Northern Lancaster County (Ephrata) Medical Group primary care physicians and specialists. If we don’t have a WellSpan Medical Group physician to meet your criteria, the search will expand to include community physicians who partner with WellSpan Medical Group physicians through the WellSpan Provider Network or provide care to patients on the Medical Staffs of WellSpan’s Hospitals.


Schedule Your Next Appointment Online with MyWellSpan

Use your MyWellSpan patient portal any time to view available appointments, and pick the date and time that best suits your schedule.

Go to MyWellSpan

New to this practice?

If you don't have a WellSpan primary care provider and would like to schedule a new patient appointment with a provider who is accepting patients, just log into your MyWellSpan account, and go to the Appointment Center section. As you progress through the scheduling process, you will be able to see the offices that are accepting new patients in relation to your zip code. If you are not enrolled in MyWellSpan, go to, call 1-866-638-1842 or speak with a member of the staff at a participating facility to sign up. New patient scheduling not available at all practices/programs.

Already a patient at this practice?

If you already have a relationship with a WellSpan practice, simply log into your account, and go to the Appointment Center section. As you progress through the scheduling process, you will be able to schedule an appointment with any provider or practice that already counts you as a patient. Online scheduling varies by practice/program.